Hedge Fund - Broadfin Capital

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information...

After all, activist hedge funds get most of their earnings from investing in companies and pushing them to provide more shareholder value.

We wrote recently about Qlt Inc (NASDAQ:QLTI) entering into an Agreement and Plan of Merger with its wholly-owned indirect subsidiary, Isotope Acquisition Corp., and Aegerion Pharmaceuticals, Inc., ...

Back in June, Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Qlt Inc.

In June, Qlt Inc (NASDAQ:QLTI) signed an Agreement and Plan of Merger with its wholly-owned indirect subsidiary, Isotope Acquisition Corp., and Aegerion Pharmaceuticals, Inc.

An amended 13D filing with the Securities and Exchange Commission showed that Kevin Kotler's Broadfin Capital has acquired more shares of Recro Pharma Inc.

Kevin Kotler's healthcare-focused fund Broadfin Capital held a 13F portfolio valued at about $1.04 billion at the end of the first quarter, according to its latest filing.

Though 2016 hasn't been great for the overall hedge fund industry so far, it is turning out to be an especially terrible year for biotech-focused hedge funds.

1  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...